Rethink Your Approach to Research
At OM1, we’re changing the research paradigm to enable rapid, cost-effective, and scalable research.
Traditional methods deliver the same results and limitations.
- Linear, rigid design
- Costly and long delays to insights
- Selection bias and lack of diversity
- Extensive use of manual processes that are burdensome for HCPs and patients
- Gaps in data
Automation changes everything.
- Flexible, reusable design
- Continuous stream of RWD
- Accelerate study timelines and drastically reduce costs
- Easily recruit high volumes of patients and minimize burden to sites and patients
- Increase patient diversity and reduce bias
- Linked data with the ability to adapt and expand
Meet OM1 Aspen
OM1 Aspen leverages our proprietary data sourcing, processing and enrichment technologies, including electronic medical records harmonization, image management, advanced medical text processing and linkage, to deliver a more efficient, cost-effective and scalable approach to research.
Tap into our networks or build new ones for automated evidence generation. Harness scientifically robust data from large and diverse populations and gain depth around patient outcomes with linked data.
Put Aspen to use today
Click the hand icon to explore OM1 Aspen.
One solution that grows with your needs
From hypothesis generation to regulatory submission, OM1 Aspen enables life sciences organizations to automate real-world data collection and grow evergreening data networks that fuel a variety of needs.
How we can help
Revolutionize your clinical research
- Achieve unparalleled cost savings benefits
The cost of developing new treatments is becoming increasingly expensive – and the pressure for ClinOps teams to reduce costs has never been greater. OM1’s solutions dramatically improve cost efficiency compared to traditional data collection methods.
- Reduce site and patient burden
Automatic prospective collection of data increases patient numbers and follow-up, while minimizing burden on sites with fewer manual tasks.
- Enhance diversity
With wider site participation and broader patient populations, results are more generalizable and individualized.
Generate high-quality data to meet regulatory needs and conduct long-term follow-up
- Meet the high bar for generating RWE for regulatory
Fit-for-purpose, transparent, and traceable real-world data meet the high-quality, auditable data requirements for regulatory evidence.
- Minimize the risk of loss to follow-up
Patient consent paired with automation allows for additional prospective data collection, increasing patient numbers and follow-up for deeper, actionable insights.
- Generate complementary evidence to fill gaps
Build external control arms to mirror clinical trial patients or other real-world studies to demonstrate generalizability and to fill evidence gaps needed for regulatory decision making
Drive evidence-based medicine forward with rapid, digitized data collection and automated registries
- Harness actionable insights to inform program strategy
Leverage robust, clinically deep data to support your program strategy and accelerate Medical Affairs’ position as a strategic pillar in your organization.
- Demonstrate patient value in real-world settings
Bridge the insight gap. Analyze, disseminate, and communicate real-world insights to optimize experiences for patients and physicians.
- Generate robust real-world data to assess outcomes, evaluate
effectiveness and understand patient journeys
Create automated, flexible registries for answering different research questions, engaging with HCPs and patients, and fueling publications.
Break data silos to unlock a continuous stream of RWE for your evolving organizational needs
- Achieve a better understanding of patient journeys, clinical endpoints, and outcomes with direct and linked data
Fill in the gaps with by linking additional data such as hard-to-find quality specialty data, patient reported outcomes (PROs), images, and labs.
Thought Leader in Registries
OM1 experts have been leading best practices in registries and observational studies for decades, including the AHRQ Registries for Evaluating Patient Outcomes: A User’s Guide, now in it’s 4th edition.
Changing the Research Paradigm
Study designs that use RWD offer a potential tool for the efficient generation of RWE to inform regulatory decision-making. Read: Using real-world evidence to support a changing paradigm for cancer screening: A commentary
OM1 Aspen supports large-scale comparative effectiveness and outcomes studies. Read about our largest study: Mammographic Screening in Routine Practice: Multisite Study of Digital Breast Tomosynthesis and Digital Mammography Screenings
Meet our expert
Sonja Wustrack is the Managing Director of Integrated Evidence Generation at OM1, responsible for the design and execution of OM1 retrospective and prospective registries using networks and platforms. Sonja has over 20 years experience working in the Pharma/CRO space in various positions across Operations, Sales, Account Management and Strategy.
Prior to OM1, Sonja was at Verana Health where she led the Commercial Operations teams. Sonja spent a number of years in the CRO space, most recently at IQVIA, where she held a number of positions from Account Management, Demand Generation, Clinical Delivery and RWE offering development. Sonja has a MPH in Epidemiology from Tulane University School of Public Health and a BA in Biology from Vassar College.
Ready to talk?
See how OM1 Aspen can help you reach your research goals faster and more efficiently.